Drug Trial Radar · NCT06925737
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,440
Planned (sponsor's estimate)
Start
May 13, 2025
Primary completion
Jun 26, 2028
Study completion Jan 6, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Conditions
- Prostate Cancer
- Prostatic Neoplasms
Interventions
Ifinatamab deruxtecanDrug
Administered via intravenous (IV) infusion every 3 weeks (q3w) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
DocetaxelDrug
Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
PrednisoneDrug
Oral tablet administered once per day or per approved product label
Rescue MedicationDrug
Before administering each dose of I-DXd, premedication is required for prevention of nausea and vomiting with a 2 or 3 drug combination regimen (eg, corticosteroids with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist and other drugs as indicated) per approved product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 36 months
- Radiographic Progression Free Survival (rPFS)Time frame: Up to approximately 36 months
Locations
303 sites in 35 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix ( Site 0044)
Phoenix, Arizona · Recruiting
Community Cancer Institute ( Site 0081)
Clovis, California · Recruiting
City of Hope Comprehensive Cancer Center ( Site 0049)
Duarte, California · Recruiting
City of Hope Lennar Foundation Cancer Center ( Site 0059)
Irvine, California · Recruiting
Moores Cancer Center ( Site 0010)
La Jolla, California · Recruiting
Veterans Affairs Long Beach Healthcare System ( Site 0058)
Long Beach, California · Recruiting
Cedars-Sinai Medical Center ( Site 0068)
Los Angeles, California · Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 0002)
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006)
Orange, California · Recruiting
Stanford Cancer Center ( Site 0046)
Palo Alto, California · Recruiting
Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053)
Aurora, Colorado · Recruiting
Yale-New Haven Hospital-Yale Cancer Center ( Site 0050)
New Haven, Connecticut · Recruiting
Veterans Affairs Connecticut Healthcare System ( Site 0062)
West Haven, Connecticut · Recruiting
The GW Medical Faculty Associates ( Site 0057)
Washington D.C., District of Columbia · Completed
Washington DC Veterans Affairs Medical Center ( Site 0056)
Washington D.C., District of Columbia · Recruiting
Clermont Oncology Center ( Site 0087)
Clermont, Florida · Recruiting
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077)
Jacksonville, Florida · Recruiting
Mid Florida Hematology and Oncology Center ( Site 0086)
Orange City, Florida · Recruiting
Emory University School of Medicine- Grady Campus ( Site 0103)
Atlanta, Georgia · Recruiting
Winship Cancer Institute, Emory University ( Site 0003)
Atlanta, Georgia · Recruiting
Rush University Medical Center-Hematology and Oncology ( Site 0028)
Chicago, Illinois · Recruiting
University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063)
Chicago, Illinois · Recruiting
University of Kentucky Chandler Medical Center ( Site 0048)
Lexington, Kentucky · Recruiting
Greenebaum Comprehensive Cancer Center ( Site 0021)
Baltimore, Maryland · Recruiting
Beth Israel Deaconess Medical Center ( Site 0043)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute ( Site 0012)
Boston, Massachusetts · Recruiting
University of Michigan ( Site 0005)
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital ( Site 0035)
Detroit, Michigan · Recruiting
Cancer and Hematology Centers of Western Michigan ( Site 0015)
Grand Rapids, Michigan · Recruiting
Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0078)
Rochester, Minnesota · Recruiting
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0032)
Saint Louis Park, Minnesota · Recruiting
HealthPartners Cancer Center at Regions Hospital ( Site 0052)
Saint Paul, Minnesota · Recruiting
St. Vincent Frontier Cancer Center-Research ( Site 0037)
Billings, Montana · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island ( Site 0076)
Grand Island, Nebraska · Completed
Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026)
Omaha, Nebraska · Completed
Comprehensive Cancer Centers of Nevada ( Site 0082)
Las Vegas, Nevada · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)
Hackensack, New Jersey · Recruiting
University of New Mexico Comprehensive Cancer Center ( Site 0022)
Albuquerque, New Mexico · Recruiting
Icahn School of Medicine at Mount Sinai ( Site 0009)
New York, New York · Recruiting
Great Lakes Cancer Care ( Site 0047)
Williamsville, New York · Recruiting
Showing 40 of 303 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.